Michael Keyoung
Chairman chez AffaMed Therapeutics
Profil
Michael has over 20 years of experience as a physician, investor and a healthcare executive.
At CBC Group, Michael has led multiple investments in biopharma companies and currently serves on the boards of CBC Group portfolio companies.
Michael launched the R-Bridge Healthcare Fund strategy at CBC Group in 2020, and opened the firm’s U.S.
core office in New York City.
Prior to joining CBC Group in 2017, Michael was President and CEO of Genexine Inc., a KOSDAQ listed biotech company developing innovative biologics in immuno-oncology, metabolic and autoimmune diseases.
He was also the Founding Managing Partner of Portola Capital Partners, a healthcare-dedicated investment firm, and the President of Catalyst Biosciences, a clinical stage biotech company.
Michael previously also held the position of Managing Director and head of Pan-Asia of U.S.
venture capital firm Burrill & Company where he oversaw investments in private and public companies globally.
Throughout his career, he has advised leading healthcare companies such as Eli Lilly, Bausch & Lomb, UCB, Samsung Electronics/ Samsung Biologics, and Green Cross in global drug development, commercial strategies and partnerships, or their regional expansion to Asia.
Michael received his Medical Doctorate and Ph.D.
in Neuroscience and Neurology from Cornell University Weill Medical College and Memorial Sloan Kettering Cancer Center.
He was a Howard Hughes Medical Institute Research fellow and received his clinical surgical training at the University of California, San Francisco.
He did his biomedical fellowship at the Memorial Sloan Kettering Institute and at Rockefeller University in New York and also studied Private Equity and Venture Capital at Harvard Business School Executive Education.
Postes actifs de Michael Keyoung
| Sociétés | Poste | Début |
|---|---|---|
Portola Capital Partners
 Portola Capital Partners Investment ManagersFinance Portola Capital Partners is a private equity firm founded in 1992. The firm is headquartered in Silicon Valley, California. | Private Equity Investor | 01/01/2013 |
AffaMed Therapeutics
 AffaMed Therapeutics Pharmaceuticals: MajorHealth Technology AffaMed Therapeutics is a Chinese company focused on providing innovative treatments to patients. The company is based in Shanghai, CN. The company's mission and vision are centered around improving patient access to these treatments. The company has a pipeline of products in development to achieve this goal. and has subsidiaries in United States and Hong Kong. The CEO of the company is Dayao Zhao. | Chairman | 01/01/2019 |
InxMed Biotechnology Nanjing Co., Ltd.
 InxMed Biotechnology Nanjing Co., Ltd. BiotechnologyHealth Technology InxMed Biotechnology Nanjing Co., Ltd. is a clinical-stage biotech company established in 2018, dedicated to developing innovative therapies to overcome treatment resistance, especially anti PD-1/PD-L1 resistance. InxMed is based in Nanjing, China, and has teams located in Shanghai and Beijing, with hubs in San Francisco and Melbourne. The Chinese company's innovations are inspired by patients and driven by in-depth understanding of disease biology and pharmacology. InxMed has raised tens of millions of US dollars in series A round financing and has an integrated high-caliber research and clinical development team across China, the US, and Australia. The company has built a unique innovative pipeline through its own discovery research and development and collaborative research and development. The company was founded in 2018 by Fei Cao and Zai Qi Wang, with Zai Qi Wang serving as the CEO since then. | Director/Board Member | 01/03/2020 |
| C-Bridge Capital Partners LLC | Corporate Officer/Principal | - |
CBC Group (Singapore) Pte. Ltd.
 CBC Group (Singapore) Pte. Ltd. Investment ManagersFinance CBC Group (Singapore) Pte. Ltd.(CBC Group) is a private equity firm founded in 2014 by Wei Fu. The firm is headquartered in Singapore with additional offices in New York, Hong Kong, Shanghai and Beijing and is wholly owned by CBC Group Investment Management Ltd. | Private Equity Investor | 01/01/2017 |
C-Bridge Capital LLC
 C-Bridge Capital LLC Investment ManagersFinance C-Bridge Capital LLC (C-Bridge Capital) is a venture capital subsidiary of CBC Group founded in 2019 by Fu Wei. The firm is headquartered in New York.. | Private Equity Investor | 01/01/2017 |
Anciens postes connus de Michael Keyoung
| Sociétés | Poste | Fin |
|---|---|---|
| CALCIMEDICA, INC. | Director/Board Member | 01/02/2021 |
| EVEREST MEDICINES LIMITED | Director/Board Member | 31/12/2019 |
I-MAB Biopharma Co., Ltd.
 I-MAB Biopharma Co., Ltd. BiotechnologyHealth Technology I-Mab Biopharma (Shanghai) Co., Ltd. engages in the development of biologics. It focuses on monoclonal antibodies or bi-specific antibodies in the areas of immuno-oncology and autoimmune diseases. The company was founded by Jingwu Zang in March 2017 and is headquartered in Shanghai, China. | Director/Board Member | 31/12/2018 |
| ░░ ░░░░░ ░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░ ░░░░░░░░░ ░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Formation de Michael Keyoung
| Weill Cornell Medical College | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| GENEXINE, INC. | Health Technology |
| EVEREST MEDICINES LIMITED | Health Technology |
| Entreprise privées | 14 |
|---|---|
SK Holdings, Inc.
 SK Holdings, Inc. BroadcastingConsumer Services Part of Match Group, Inc., SK Holdings, Inc. is a private company based in New York, NY. | Consumer Services |
Graybug Vision, Inc.
 Graybug Vision, Inc. Pharmaceuticals: MajorHealth Technology Graybug Vision, Inc. develops ophthalmic drugs. It focus on developing drug delivery therapies for the treatment of eye diseases such as age-related macular degeneration and glaucoma. The company was founded by Justin S. Hanes, Peter John McDonnell, Christy Wyskiel and Peter A. Campochiaro in May 2011 and is headquartered in Redwood City, CA. | Health Technology |
Burrill LLC
 Burrill LLC Investment ManagersFinance Burril LLC (Burrill) is a private equity/venture capital firm founded in 1994 by G. Steven. The firm is headquartered in San Francisco, California. | Finance |
Korea Evaluation Institute of Industrial Technology
 Korea Evaluation Institute of Industrial Technology Miscellaneous Commercial ServicesCommercial Services Korea Evaluation Institute of Industrial Technology operates as a research institute to develop technology for domestic industries. The private company is based in Daegu, South Korea. The South Korean company is ultimately controlled by the Government of South Korea. | Commercial Services |
Catalyst Biosciences, Inc.
 Catalyst Biosciences, Inc. BiotechnologyHealth Technology Catalyst Biosciences, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of novel medicines to address serious medical conditions. The company was founded on March 7, 1997 and is headquartered in South San Francisco, CA. | Health Technology |
I-Mab Bio-tech (Tianjin) Co. Ltd.
 I-Mab Bio-tech (Tianjin) Co. Ltd. BiotechnologyHealth Technology I-Mab Bio-tech (Tianjin) Co., Ltd. engages in the research and development of medicine and biological products. Its business activities include investment information consultation, and health information services. The company was founded on April 19, 2012 and is headquartered in Tianjin, China. | Health Technology |
| C-Bridge Capital Partners LLC | |
CBC Group (Singapore) Pte. Ltd.
CBC Group (Singapore) Pte. Ltd. Investment ManagersFinance CBC Group (Singapore) Pte. Ltd.(CBC Group) is a private equity firm founded in 2014 by Wei Fu. The firm is headquartered in Singapore with additional offices in New York, Hong Kong, Shanghai and Beijing and is wholly owned by CBC Group Investment Management Ltd. | Finance |
I-MAB Biopharma Co., Ltd.
I-MAB Biopharma Co., Ltd. BiotechnologyHealth Technology I-Mab Biopharma (Shanghai) Co., Ltd. engages in the development of biologics. It focuses on monoclonal antibodies or bi-specific antibodies in the areas of immuno-oncology and autoimmune diseases. The company was founded by Jingwu Zang in March 2017 and is headquartered in Shanghai, China. | Health Technology |
PT Kalbe Genexine Biologics
 PT Kalbe Genexine Biologics BiotechnologyHealth Technology PT Kalbe Genexine Biologics is a clinical-stage biotech company based in Jakarta, Indonesia. The Indonesian company specializes in licensing novel biologics and biosimilars in oncology and high-specialty therapeutic areas, as well as contract manufacturing. The company was founded in 2016 and is backed by Kalbe and Genexine, as well as US private equity giant General. The CEO is Sie Djohan. | Health Technology |
AffaMed Therapeutics
AffaMed Therapeutics Pharmaceuticals: MajorHealth Technology AffaMed Therapeutics is a Chinese company focused on providing innovative treatments to patients. The company is based in Shanghai, CN. The company's mission and vision are centered around improving patient access to these treatments. The company has a pipeline of products in development to achieve this goal. and has subsidiaries in United States and Hong Kong. The CEO of the company is Dayao Zhao. | Health Technology |
InxMed Biotechnology Nanjing Co., Ltd.
InxMed Biotechnology Nanjing Co., Ltd. BiotechnologyHealth Technology InxMed Biotechnology Nanjing Co., Ltd. is a clinical-stage biotech company established in 2018, dedicated to developing innovative therapies to overcome treatment resistance, especially anti PD-1/PD-L1 resistance. InxMed is based in Nanjing, China, and has teams located in Shanghai and Beijing, with hubs in San Francisco and Melbourne. The Chinese company's innovations are inspired by patients and driven by in-depth understanding of disease biology and pharmacology. InxMed has raised tens of millions of US dollars in series A round financing and has an integrated high-caliber research and clinical development team across China, the US, and Australia. The company has built a unique innovative pipeline through its own discovery research and development and collaborative research and development. The company was founded in 2018 by Fei Cao and Zai Qi Wang, with Zai Qi Wang serving as the CEO since then. | Health Technology |
C-Bridge Capital LLC
C-Bridge Capital LLC Investment ManagersFinance C-Bridge Capital LLC (C-Bridge Capital) is a venture capital subsidiary of CBC Group founded in 2019 by Fu Wei. The firm is headquartered in New York.. | Finance |
Portola Capital Partners
Portola Capital Partners Investment ManagersFinance Portola Capital Partners is a private equity firm founded in 1992. The firm is headquartered in Silicon Valley, California. | Finance |
